ATRC

Business Context and Reporting Period

Company: AtriCure, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: AtriCure is a medical device company specializing in cardiac surgical ablation systems, primarily the Isolator system, used to treat atrial fibrillation (AF). While the FDA has cleared the products for cardiac tissue ablation, their use for treating AF is currently considered "off-label." The company operates in a single segment with sales primarily in the United States (85%) and internationally (15%).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 14.4% to $55.3 million, driven by new product introductions (Coolrail, MicroPace ORLab) and increased unit sales to international customers.
• Gross Margin Compression: Gross margin decreased from 79.0% to 76.1%. This was primarily due to the introduction of new products with higher costs of revenue (e.g., ORLab system) and a higher mix of international sales which carry lower average selling prices.
• Operating Expenses: Total operating expenses increased to $53.0 million. Selling, general, and administrative (SG&A) expenses rose $2.7 million due to increased personnel costs and non-cash compensation, while R&D expenses decreased slightly by $0.4 million.
• Debt Structure: The company entered a new $10.0 million revolving credit facility in July 2008. As of year-end, $6.0 million was outstanding, and $6.0 million was held as restricted cash to secure the facility.
• Stock Performance: The stock price declined significantly in the fourth quarter of 2008, with a low of $2.00, compared to a high of $14.05 in the first quarter.

Guidance, Outlook, Risks, and Contingencies

• Regulatory Outlook: The company is conducting the ABLATE clinical trial to seek FDA approval for the Isolator system for permanent AF treatment, with a potential PMA filing in 2010. The Left Atrial Appendage Exclusion System is expected to receive FDA clearance in the first half of 2010.
• DOJ Investigation: The U.S. Department of Justice is investigating potential False Claims Act violations regarding the marketing of products for off-label AF treatment and the use of incorrect billing codes for Medicare reimbursement. The company states it is cooperating and has not recorded a liability as the outcome cannot be estimated.
• Legal Proceedings: Two securities class action lawsuits are pending against the company and certain officers, alleging violations of federal securities laws related to disclosures about marketing practices and billing.
• Goodwill Impairment Risk: Due to a drop in market capitalization below net book value in early 2009, the company anticipates performing a goodwill impairment test in Q1 2009, which could result in a write-off of up to $6.8 million.
• Liquidity: Management believes current cash and cash equivalents are sufficient to meet capital requirements for at least the next 12 months, though future funding may be required for clinical trials and operations.

Investor Verification Checklist

• Off-Label Use Status: Verify the current regulatory stance on the "off-label" use of the Isolator system for AF treatment and the timeline for FDA approval.
• DOJ Investigation Outcome: Monitor developments regarding the Department of Justice investigation into marketing practices and Medicare billing codes.
• Goodwill Impairment: Review Q1 2009 filings for the results of the goodwill impairment test and potential impact on net income.
• Clinical Trial Results: Track the enrollment and results of the ABLATE and EXCLUDE clinical trials, which are critical for future revenue growth.
• Reimbursement Policies: Assess changes in Medicare and private payer reimbursement policies for surgical AF treatments, which directly impact hospital adoption.